Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL

por Reusing, Sarah B., Vallera, Dan A., Manser, Angela R., Watrin, Titus, Bhatia, Sanil, Felices, Martin, Miller, Jeffrey S., Uhrberg, Markus, Babor, Florian
Publicado 2021

P325: APPLICATIONS OF HIGH-THROUGHPUT DRUG SCREENING AS DRUG REPURPOSING STRATEGY FOR POOR OUTCOME SUBGROUPS OF PEDIATRIC B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA

por Oikonomou, Athanasios, Valsecchi, Luigia, Quadri, Manuel, Watrin, Titus, Scharov, Katerina, Tu, Jia-Wey, Bhatia, Sanil, Bardini, Michela, Fazio, Grazia, Borkhardt, Arndt, Palmi, Chiara, Cazzaniga, Giovanni
Publicado 2023

Recurrent Germline Variant in RAD21 Predisposes Children to Lymphoblastic Leukemia or Lymphoma

por Schedel, Anne, Friedrich, Ulrike Anne, Morcos, Mina N. F., Wagener, Rabea, Mehtonen, Juha, Watrin, Titus, Saitta, Claudia, Brozou, Triantafyllia, Michler, Pia, Walter, Carolin, Försti, Asta, Baksi, Arka, Menzel, Maria, Horak, Peter, Paramasivam, Nagarajan, Fazio, Grazia, Autry, Robert J, Fröhling, Stefan, Suttorp, Meinolf, Gertzen, Christoph, Gohlke, Holger, Bhatia, Sanil, Wadt, Karin, Schmiegelow, Kjeld, Dugas, Martin, Richter, Daniela, Glimm, Hanno, Heinäniemi, Merja, Jessberger, Rolf, Cazzaniga, Gianni, Borkhardt, Arndt, Hauer, Julia, Auer, Franziska
Publicado 2022